Founder BRCA1 mutations in Nepalese population
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Founder mutation is a heritable genetic alteration observed with high frequency in a geographically and culturally isolated population where one or more ancestors becomes the forebearer of the altered gene. The current study reports two founder mutations in the <i>BRCA1</i> gene in the Nepalese people.Methods: Germline <i>BRCA</i> testing in all surface epithelial ovarian cancers and the selected case of breast, prostate, and pancreatic cancers has been the standard practice from 2016 to 2021. One thousand one hundred thirtythree probands were screened for germline <i>BRCA</i> variants by next generation sequencing. The variants were classified as per the American Society of Medical Genetics and Genomics recommendations. Pathogenic (class V) and likely pathogenic (class IV) were considered clinically relevant and utilized for cascade screening.Results: Nepalese population made up a subcohort of 5.12% (58/1,133) of probands tested for germline <i>BRCA1/2</i> variants. Twenty-seven of these 58 tested harbored pathogenic genetic alterations in <i>BRCA1/2</i> genes, with 23 being <i>BRCA1</i> mutant. Sixteen of 23 <i>BRCA1</i> mutant cases shared one common pathogenic mutation c.2214_2215insT (p.Lys739Ter) (NM_007294.4). Additionally, a second highly recurrent mutation in <i>BRCA1</i> gene c.5068A>T (p.Lys1690Ter) (NM_007294.4) was noted in six patients from this population.Conclusions: The overwhelming abundance of the above two variants in a geographically confined population confers these two genetic alterations a status of founder mutations amongst the people of Nepal. A more extensive population-based study to reaffirm these findings will help establish a dual site-specific germline testing similar to the “Multisite-3-assay” in Ashkenazi Jews as the primary screening tool, especially in a resource-constrained environment.
Abstract
Background: Founder mutation is a heritable genetic alteration observed with high frequency in a geographically and culturally isolated population where one or more ancestors becomes the forebearer of the altered gene. The current study reports two founder mutations in the <i>BRCA1</i> gene in the Nepalese people.Methods: Germline <i>BRCA</i> testing in all surface epithelial ovarian cancers and the selected case of breast, prostate, and pancreatic cancers has been the standard practice from 2016 to 2021. One thousand one hundred thirtythree probands were screened for germline <i>BRCA</i> variants by next generation sequencing. The variants were classified as per the American Society of Medical Genetics and Genomics recommendations. Pathogenic (class V) and likely pathogenic (class IV) were considered clinically relevant and utilized for cascade screening.Results: Nepalese population made up a subcohort of 5.12% (58/1,133) of probands tested for germline <i>BRCA1/2</i> variants. Twenty-seven of these 58 tested harbored pathogenic genetic alterations in <i>BRCA1/2</i> genes, with 23 being <i>BRCA1</i> mutant. Sixteen of 23 <i>BRCA1</i> mutant cases shared one common pathogenic mutation c.2214_2215insT (p.Lys739Ter) (NM_007294.4). Additionally, a second highly recurrent mutation in <i>BRCA1</i> gene c.5068A>T (p.Lys1690Ter) (NM_007294.4) was noted in six patients from this population.Conclusions: The overwhelming abundance of the above two variants in a geographically confined population confers these two genetic alterations a status of founder mutations amongst the people of Nepal. A more extensive population-based study to reaffirm these findings will help establish a dual site-specific germline testing similar to the “Multisite-3-assay” in Ashkenazi Jews as the primary screening tool, especially in a resource-constrained environment.
참고문헌 (26)
- Kuchenbaecker KB, "Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2mutation carriers", JAMA, 317, pp.2402~2416 (2017)
- Antoniou A, "Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history : a combined analysis of 22 studies", Am J Hum Genet, 72, pp.1117~1130 (2003)
- Chen S, "Meta-analysis of BRCA1 and BRCA2 penetrance", J Clin Oncol, 25, pp.1329~1333 (2007)
- Mehta A, "BRCA1 and BRCA2 mutations in ovarian cancer", J Curr Oncol, 1, pp.1~4 (2018)
- Tai YC, "Breast cancer risk among male BRCA1 and BRCA2 mutation carriers", J Natl Cancer Inst, 99, pp.1811~1814 (2007)
- Levy-Lahad E, "Cancer risks among BRCA1 and BRCA2mutation carriers", Br J Cancer, 96, pp.11~15 (2007)
- Oh M, "The association of BRCA1and BRCA2 mutations with prostate cancer risk, frequency, and mortality : a meta-analysis", Prostate, 79, pp.880~895 (2019)
- Nyberg T, "Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers : a prospective cohort study", Eur Urol, 77, pp.24~35 (2020)
- Hu C, "Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer", JAMA, 319, pp.2401~2409 (2018)
- Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. Preventive Services Task Force Recommendation, "Nelson HD", Oregon Health and Science University, ~, pp.12-05164-EF-1 (2013)
- Hall MJ, "BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer", Cancer, 115, pp.2222~2233 (2009)
- Balmana J, "BRCA in breast cancer : ESMO clinical practice guidelines", Ann Oncol, 22(Suppl 6), pp.vi31~vi34 (2011)
- Rosenthal E, "Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry", Breast Cancer Res Treat, 149, pp.223~227 (2015)
- Yadava YP, "Linguistic diversity in Nepal: perspectives on language policy", International Seminar on Constitutionalism and Diversity in Nepal (2007)
- Daly MB, "NCCN guidelines insights:genetic", familial high-risk assessment: breast, ovarian, and pancreatic, version 1.2020, 2020, pp.18, 380~391
- Mehta A, "Germline BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance associated with breast", ovarian cancer : a report from North India, 2018, pp.10, 6505~6516
- Lih CJ, "Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial : molecular analysis for therapy choice clinical trial", J Mol Diagn, 19, pp.313~327 (2017)
- Richards S, "Standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology", Genet Med, 17, pp.405~424 (2015)
- Gao J, "Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal", Sci Signal, 6, pp.pl1~ (2013)
- Cerami E, "The cBio cancer genomics portal : an open platform for exploring multidimensional cancer genomics data", Cancer Discov, 2, pp.401~404 (2012)
- Tonin P, "Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families", Nat Med, 2, pp.1179~1183 (1996)
- Kopanos C, "VarSome : the human genomic variant search engine", Bioinformatics, 35, pp.1978~1980 (2019)
- Schwarz JM, "MutationTaster2 : mutation prediction for the deep-sequencing age", Nat Methods, 11, pp.361~362 (2014)
- Fokkema IF, "LOVD v.2.0: the next generation in gene variant databases", Hum Mutat, 32, pp.557~563 (2011)
- Karczewski KJ, "The mutational constraint spectrum quantified from variation in 141, 456 humans", Nature, 581, pp.434~443 (2020)
- Landrum MJ, "ClinVar : improving access to variant interpretations and supporting evidence", Nucleic Acids Res, 46, pp.D1062~7 (2018)